A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U.
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: David Michael Jackman, Opeyemi Jegede, Marjorie Glass Zauderer, Edith P. Mitchell, James Zwiebel, Robert James Gray, Shuli Li, Lisa McShane, Lawrence Rubinstein, David R Patton, Paul M. Williams, Stanley R. Hamilton, Barbara A. Conley, Carlos L. Arteaga, Lyndsay Harris, Peter J. O'Dwyer, Alice P. Chen, Keith Flaherty
Institutions: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Thomas Jefferson University, Sidney Kimmel Cancer Center, National Cancer Institute, Frederick National Laboratory for Cancer Research, The University of Texas MD Anderson Cancer Center, National Institutes of Health, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Pennsylvania Hospital, University of Pennsylvania, Harvard University, Massachusetts General Hospital
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W3167628565